Since 1989, strains of Salmonella typhi resistant to chloramphenicol, ampicillin, and trimethoprim (i.e., multidrug-resistant [MDR] strains) have been responsible for numerous outbreaks in countries in the Indian subcontinent, Southeast Asia, and Africa. MDR strains have also been isolated with increasing frequency from immigrant workers in countries in the Arabian Gulf, as well as in developed countries from returning travelers. In all MDR strains so far examined, multiple resistance has been encoded by plasmids of the H 1 incompatibility group. As a result of the widespread dissemination of such strains, chloramphenicol can no longer be regarded as the first-line drug for typhoid fever. Because strains are also resistant to ampicillin and trimethoprim, the efficacy of these antibiotics has also been impaired, and ciprofloxacin is now the drug of choice for typhoid fever. Chromosomally encoded resistance to ciprofloxacin has now been observed in a small number of strains isolated in the United Kingdom from patients returning from the Indian subcontinent, and in at least one case the patient did not respond to treatment with this antibiotic. It is regrettable that resistance to ciprofloxacin has now emerged in MDR S. typhi, and it is of paramount importance to limit the unnecessary use of this vital drug so that its efficacy should not be further jeopardized.
Although precise figures are not available, in 1986 the number of cases of typhoid fever worldwide was estimated at 33 million [1] . The disease is endemic in many developing countries, particularly in the Indian subcontinent, South and Central America, and Africa, with an estimated mean incidence (per 100,000 people per annum) of 150 in South America and 900 in Asia [2] . Travelers to these areas are at risk, and in developed countries of northwest Europe, most cases involve returning travelers. In Britain, for example, -200-300 cases occur each year, an overall incidence of -0.5 per 100,000 [3] , and at least 70% of the patients have a history of recent foreign travel.
Emergence of Drug Resistance
Treatment with an appropriate antibiotic is essential for typhoid fever, and because of the nature of the disease it should commence as soon as the clinical diagnosis is made rather than after the results of antimicrobial susceptibility tests are available. Until the mid-1970s chloramphenicol was the undisputed drug for treatment of typhoid fever, and in developed countries the use of this antibiotic resulted in a reduction in mortality from 10% to <2% [4] .
Although before 1970 a few sporadic isolations of chloramphenicol-resistant Salmonella typhi had been reported from Aden, Chile, and Kuwait [5] , the first epidemic caused by a chloramphenicol-resistant strain was that which occurred in Mexico in 1972 [6, 7] . At about the same time, there was a second substantial outbreak in Kerala, India [8] , and in both outbreaks mortality was high. In the succeeding 5 years outbreaks occurred in several other countries, notably, Vietnam, Indonesia, Korea, Chile, and Bangladesh (for review, see [9] ).
A notable feature of all chloramphenicol-resistant strains from outbreaks in Mexico, the Indian subcontinent, and Southeast Asia was that although the strains belonged to different Vi phage types, resistance to chloramphenicol was encoded by a plasmid of the H 1 incompatibility group, often in combination with resistance to streptomycin, sulfonamides, and tetracyclines (antibiogram, CSSuT; see footnote to table 1) [7, 9] .
Outbreaks of Multidrug-Resistant Typhoid
Since 1989 outbreaks caused by strains of S. typhi resistant to chloramphenicol, ampicillin, and trimethoprim and with additional resistance to streptomycin, sulfonamides, and tetracyclines (antibiogram, ACSSuTTm; see footnote to table 1) have been reported in many developing countries, especially Pakistan [10, 11] and India [9, [12] [13] [14] . Such strains have been termed multidrug-resistant (MDR). MDR strains have also caused outbreaks in Bangladesh [15] , several countries in Southeast Asia [16] , and both North and South Africa [17, 18] , and in 1991 there was a small outbreak associated with a foodhandler in a take-out restaurant in Britain [19] (table 1) . MDR strains linked to immigrant workers from the Indian subcontinent have been isolated with increasing frequency in several countries in the Arabian Gulf [20] [21] [22] .
The most common Vi phage types have been those of El and M 1, but outbreaks have been caused by MDR strains of Vi phage types 51 and 0 in India [13, 14] , Vi phage type M1 * A = ampicillin; C = chloramphenicol; K = kanamycin; S = streptomycin; Su = sulfonamides; T = tetracyclines; Tm = trimethoprim.
in the United Kingdom [19] , Vi phage type A in South Africa [18] , and Vi phage types E2, Cl, and Dl-N in Egypt [17] . The phage types of MDR strains isolated in the Arabian Gulf (E 1, M 1, and 51) correspond to those that have caused outbreaks in the Indian subcontinent. Strains of Vi phage types El and M1 have also been isolated in Australia [19] and Canada [23] . One outbreak of particular interest was that which occurred in the Philippines (metropolitan Manila) from July 1993 to April 1994, in which 252 cases of MDR S. typhi in 13 hospitals were reported [16] ; the strains were not phage-typed. The strains were resistant to chloramphenicol, co-trimoxazole, kanamycin, streptomycin, and tetracyclines (antibiogram, CKSSuTTm; see footnote to table 1) but susceptible to ampicillin. Although the vehicle of infection was not microbiologically confirmed, epidemiological findings suggested an association between typhoid fever and the consumption of flavored-ice drinks purchased from street vendors.
The recent explosive emergence in developing countries of strains of S. typhi with resistance to trimethoprim and ampicillin has caused many problems, as since 1980 these antibiotics had been used extensively for the treatment of patients infected with chloramphenicol-resistant strains [24] . Without exception, in all outbreaks of MDR S. typhi so far studied, the complete spectrum of multiple resistance has been encoded by plasmids of the H 1 incompatibility group.
Drug Resistance in British Isolates
In the United Kingdom, of 2,356 strains of S. typhi isolated between 1978 and 1985, only six (0.25%) were resistant to chloramphenicol at a clinically significant level (MIC, >32 mg/L). On the basis of these findings, in 1987 it was recommended that in the United Kingdom chloramphenicol should remain the first-line drug for treatment of typhoid fever and, in particular, that it should be used until the results of laboratory susceptibility tests are known [25] . In the succeeding 4-year period (1986-1989), the isolation of chloramphenicol-resistant S. typhi from patients in the United Kingdom increased slightly, from 0.25% to 1.5% [26] , but the increase was not considered sufficient to justify altering the recommendation made in 1987.
The situation has changed dramatically since 1990. In that year 20% of strains were resistant not only to chloramphenicol but also to trimethoprim (MIC, > 125 mg/L) and ampicillin (MIC, > 125 mg/L) [21] . The situation has worsened in the succeeding 5 years, and since 1994 about 35% of strains from patients with typhoid fever have been resistant to chloramphenicol (table 2) ; the majority of chloramphenicol-resistant strains also are resistant to ampicillin and trimethoprim [27] .
In 1990 the majority of chloramphenicol-resistant strains isolated in the United Kingdom belonged to Vi phage type M1 and were from patients recently returned from Pakistan, although some strains of Vi phage type El were also isolated [21] . In subsequent years the proportion of MDR strains belonging to Vi phage type El has increased, and in 1995 almost all MDR strains belonged to this phage type (table 3) .
From 1990 to 1993 the majority of patients infected with MDR strains of Vi phage type El had recently returned from India, but since 1994 an increasing number of patients infected with MDR Vi phage type El had recently returned from Pakistan. Other countries visited by patients from whom MDR S. typhi has been isolated include Sri Lanka, Bangladesh, Nepal, and Somalia [27] . In all MDR S. typhi isolated in the United Kingdom since 1990, resistance to chloramphenicol, ampicillin, and trimethoprim, together with resistance to streptomycin and sulfonamides (antibiogram, ACSSuTTm; see footnote to table 1), has been encoded by a plasmid of the H 1 incompatibility group [9, 21] .
Recommendations for Therapy
MDR S. typhi is now endemic in many developing countries but also has been isolated from returning travelers in developed countries. As a result of the proliferation of such strains, the use of chloramphenicol has been compromised, and that of ampicillin and trimethoprim similarly impaired. In October 1990, because 20% of strains of S. typhi isolated in the United Kingdom were resistant to chloramphenicol, it was suggested that physicians in the United Kingdom should consider ciprofloxacin as an alternative to chloramphenicol for the treatment of enteric fever [26] .
In 1991, in light of the increasing isolation of MDR strains in the United Kingdom after reports of outbreaks in the Indian subcontinent and Arabian Gulf, the use of ciprofloxacin for the treatment of typhoid was recommended, particularly for patients returning from areas where MDR strains are endemic [21] . Ciprofloxacin is now used extensively for the treatment of typhoid in both developing and developed countries [12, 24, 28, 29] .
Resistance to Ciprofloxacin
In 1992, the isolation in the United Kingdom of an MDR strain of S. typhi Vi phage type El with plasmid-encoded resistance to chloramphenicol, ampicillin, and trimethoprim (and chromosomal resistance to ciprofloxacin at a concentration of 0.30 mg/L) was reported [19] . The patient was a 1-year-old child who had been infected in India and did not respond to treatment with ciprofloxacin [29] . Concern was expressed that resistance to this important antibiotic had appeared in an isolate of MDR S. typhi [19] .
Subsequently, chromosomally encoded ciprofloxacin resistance has been observed in a total of 14 strains of S. typhi isolated in the United Kingdom since 1991, of which 10 have also been resistant to chloramphenicol, ampicillin, and trimethoprim [27] . All MDR strains with additional resistance to ciprofloxacin have belonged to Vi phage type El . Patients infected with such strains had recently returned from several countries in the Indian subcontinent, where this antibiotic has been used to control outbreaks of MDR typhoid since 1990 [12] .
Although it is regrettable that resistance to ciprofloxacin is now emerging, ciprofloxacin still remains the drug of choice for the treatment of MDR typhoid fever. To maintain the efficacy of ciprofloxacin for typhoid fever, however, unnecessary usage should be avoided. In particular, any prophylactic use of this important drug should be strongly discouraged. It is unfortunate that a range of fluoroquinolones, including ciprofloxacin, have been recommended for prophylaxis against traveler's diarrhea [30] .
